Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study

Detalles Bibliográficos
Autores principales: Nishikawa, Tadaaki, Hasegawa, Kosei, Yabuno, Akira, Yoshida, Hiroyuki, Yasuda, Masanori, Kozawa, Eito, Fujiwara, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165070/
https://www.ncbi.nlm.nih.gov/pubmed/27958685
http://dx.doi.org/10.3802/jgo.2017.28.e25
_version_ 1782482777921290240
author Nishikawa, Tadaaki
Hasegawa, Kosei
Yabuno, Akira
Yoshida, Hiroyuki
Yasuda, Masanori
Kozawa, Eito
Fujiwara, Keiichi
author_facet Nishikawa, Tadaaki
Hasegawa, Kosei
Yabuno, Akira
Yoshida, Hiroyuki
Yasuda, Masanori
Kozawa, Eito
Fujiwara, Keiichi
author_sort Nishikawa, Tadaaki
collection PubMed
description
format Online
Article
Text
id pubmed-5165070
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-51650702017-01-01 Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study Nishikawa, Tadaaki Hasegawa, Kosei Yabuno, Akira Yoshida, Hiroyuki Yasuda, Masanori Kozawa, Eito Fujiwara, Keiichi J Gynecol Oncol Correspondence Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017-01 2016-12-08 /pmc/articles/PMC5165070/ /pubmed/27958685 http://dx.doi.org/10.3802/jgo.2017.28.e25 Text en Copyright © 2017. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Correspondence
Nishikawa, Tadaaki
Hasegawa, Kosei
Yabuno, Akira
Yoshida, Hiroyuki
Yasuda, Masanori
Kozawa, Eito
Fujiwara, Keiichi
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
title Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
title_full Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
title_fullStr Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
title_full_unstemmed Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
title_short Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
title_sort pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165070/
https://www.ncbi.nlm.nih.gov/pubmed/27958685
http://dx.doi.org/10.3802/jgo.2017.28.e25
work_keys_str_mv AT nishikawatadaaki pazopanibasasecondlinetreatmentforuterineandovariancarcinosarcomaasingleinstitutionalstudy
AT hasegawakosei pazopanibasasecondlinetreatmentforuterineandovariancarcinosarcomaasingleinstitutionalstudy
AT yabunoakira pazopanibasasecondlinetreatmentforuterineandovariancarcinosarcomaasingleinstitutionalstudy
AT yoshidahiroyuki pazopanibasasecondlinetreatmentforuterineandovariancarcinosarcomaasingleinstitutionalstudy
AT yasudamasanori pazopanibasasecondlinetreatmentforuterineandovariancarcinosarcomaasingleinstitutionalstudy
AT kozawaeito pazopanibasasecondlinetreatmentforuterineandovariancarcinosarcomaasingleinstitutionalstudy
AT fujiwarakeiichi pazopanibasasecondlinetreatmentforuterineandovariancarcinosarcomaasingleinstitutionalstudy

Ejemplares similares